-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Serum cholinesterase (ChE) has been found to be associated with the occurrence and development of cancer
Serum cholinesterase (ChE) has been found to be associated with the occurrence and development of cancer
The study retrospectively selected 961 patients with histologically confirmed non-small cell lung cancer diagnosed
The study retrospectively selected 961 patients with histologically confirmed non-small cell lung cancer diagnosed
Among the 961 patients, the average age at diagnosis was 61.
Differences in prognosis between patients with high and low ChE levels
High serum ChE level at baseline (>= 7700 U/L) in univariate analysis (HR=0.
High serum ChE level at baseline (>= 7700 U/L) in univariate analysis (HR=0.
Analysis of OS-related factors
Baseline serum ChE levels were divided into 4 groups: group 1 (ChE < 6287 U/L), group 2 (6287 U/L <= ChE < 7700 U/L), group 3 (7700 U/L <= ChE < 8900 U/L), and 4 groups (ChE >=8900 U/L)
Baseline serum ChE levels were divided into 4 groups: group 1 (ChE < 6287 U/L), group 2 (6287 U/L <= ChE < 7700 U/L), group 3 (7700 U/L <= ChE < 8900 U/L), and 4 groups (ChE >=8900 U/L)
Comparison of the prognosis of different groups of ChE
We further performed a series of subgroup analyses based on several important patient characteristics: baseline serum NLR, chemotherapy, clinical stage, and histological type
We further performed a series of subgroup analyses based on several important patient characteristics: baseline serum NLR, chemotherapy, clinical stage, and histological type
Subgroup analysis
Taken together, our study demonstrated that baseline serum cholinesterase (ChE) could serve as an independent prognostic marker in patients with non-small cell lung cancer (NSCLC)
.
.
Studies have shown that baseline serum cholinesterase (ChE) can be used as an independent prognostic indicator in patients with non-small cell lung cancer (NSCLC)
.
Studies have shown that baseline serum cholinesterase (ChE) can be used as an independent prognostic indicator in patients with non-small cell lung cancer (NSCLC)
.
Original source:
Original source:Hailiang Ran , Jie Ma , Le Cai, et al.
Serum cholinesterase may independently predict prognosis in non-small-cell lung cancer.
BMC Cancer (2022) 22:93 https://doi.
org/10.
1186/s12885-022-09212 -0.
Serum cholinesterase may independently predict prognosis in non-small-cell lung cancer.
BMC Cancer (2022) 22:93 https://doi.
org/10.
1186/s12885-022-09212 -0.
Leave a message here
